90 results about "Bone forming" patented technology

The invention discloses application of a Chibby1 (CBY1) inhibitor in preparation of an anti-osteoporosis medicine for promoting bone formation, and belongs to the technical field of biological medicines. It is found for the first time that CBY1 can inhibit bone marrow stromal cells from differentiating into osteoblasts, and bone marrow stromal cells with CBY1 gene silencing are increased in osteoblast differentiation. According to the invention, it is proposed for the first time that osteoblast differentiation can be promoted by reducing CBY1 expression or inhibiting the CBY1 function, and the CBY1 inhibitor has the potential of increasing osteogenic activity and preventing and treating osteoporosis by inhibiting CBY1 expression or inhibiting the CBY1 function.

This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and / or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.

The invention relates to the technical field of biology, in particular to application of a GGPS1 activator, a pharmaceutical composition, a kit and a method. The invention relates to bone metabolism regulation and bone regeneration. It is found that improvement of GGPS1 expression / activity can activate TGF-beta / Smad2 / 3 by down-regulating LTBP1, so that human bone marrow mesenchymal stem cells are converted from adipogenesis to osteogenesis, and bone formation and bone defect repair are promoted. The invention provides a drug containing a GGPS1 activator and a controlled release composition for implantation, which are used for osteoporosis, bone mass reduction, delayed fracture healing and the like. The invention also provides an in-vitro screening and evaluation method and a detection kit, and the indexes such as p-Smad2 / 3, alizarin red, oil red O and the like are used for judgment. The invention realizes upstream heavy balance and has the advantages of bone promotion and fat suppression.

The present invention relates to an apparatus (10) configured and adapted to remove the flank bones (11) of a headless, slaughtered, preferably opened abdominal cavity fish (12), wherein the fish is conveyed in a conveying direction T with its tail forward and its spine (13) placed on a conveying saddle (14), the apparatus comprising at least: an upper bone guide (15) configured and adapted to guide the spine (13) from the dorsal side of the fish (12) to be processed; and a lower bone guide (16) configured and adapted to guide the ventral radii (44) of the fish (12) to be processed, the ventral radii being formed in the region from the tail to the abdominal cavity. The invention relates to a separation unit (17) for detaching fillets from the flank bones (11) surrounding the abdominal cavity of the fish (12) to be processed, wherein the separation unit (17) includes a separation mechanism (18) having a corresponding opposing unit (19) and capable of moving from a standby position to a working position and vice versa. The device (10) is characterized in that a detachment device (20) is located within the area of ​​the upper bone guide (15) and is configured and adapted to at least loosen the bone connections (21) between the individual flank bones (11) and the vertebrae (13) of at least some of the flank bones (11). The invention also relates to a corresponding slicer (40) having such a device (10) and a corresponding method.

This invention pertains to spinal pedicle screws, specifically locking spinal pedicle screws, including perforated pedicle screws and cortical bone screws that work with them. The proximal end of the self-locking master screw is thickened. A through-hole is provided in the thickened section of the pedicle screw, and the cortical bone screw is driven into the through-hole and fixed to the upper and lower cortical bone layers of the pedicle to form a triangular fixation. After the pedicle screw is implanted, both ends of the through-hole of the pedicle screw are located inside the pedicle. A hole is drilled from the posterolateral aspect of the pedicle using a special aiming device, passing forward and upward through the oblique hole of the pedicle screw, and then through the anterior and superior cortical bone of the pedicle. After measuring the length, a suitable cortical bone screw is selected, screwed in, and locked, fixing the posterolateral cortical bone, the pedicle screw, and the anterior and superior cortical bone of the pedicle. The screw is positioned in a safe area of ​​the superior cortical bone of the pedicle. The cortical bone screw is fixed to the upper and lower cortical bone of the pedicle by passing through the oblique hole, thus locking the position of the pedicle screw.

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).

Provided herein are methods of treating erosive hand osteoarthritis (OA) in a subject in need thereof, methods of reducing radiographic erosive progression, joint space narrowing, cartilage degradation, and / or bone formation in a subject in need thereof (e.g., a subject suffering from erosive hand OA), methods of inhibiting the development of new erosive joints in a subject in need thereof (e.g., a subject suffering from erosive hand OA), and methods of reducing pain in a subject with erosive hand OA. Also provided herein are uses of denosumab in the manufacture of a medicament adapted for use in a method described herein, as well as pharmaceutical compositions comprising denosumab for use in a method described herein.

The present invention relates to a biosensor that enables the detection of biomarkers related to bone metabolism through saliva samples. This biosensor, which uses a saliva sampling method and offers an economical and user-friendly solution by adopting a non-invasive approach, can detect biomarkers related to bone formation and resorption such as Procollagen Type I N-terminal Propeptide (PINP) and β-C- terminal Telopeptide (β-CTX) in saliva with high sensitivity. The present invention increases patient comfort while also providing rapid analysis, making the diagnosis and treatment processes of diseases related to bone metabolism more efficient.

The present invention addresses the problem of providing an osteogenesis promoting agent and a pharmaceutical composition for preventing or treating a disease or a symptom involving bone defect, osteogenesis imperfecta, osteogenesis disorder, and / or bone hyperresorption.　The problem is solved by: a compound represented by general formula (I), a salt thereof, or a prodrug thereof; and a composition and a pharmaceutical composition containing the same.

The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.

In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.

The invention relates to a device for bone formation, bone reshaping or healing of bone in dental, oral and maxillofacial applications, specifically in connection with installation of dental implants. The device comprises a sheet structure made of an inert material, wherein the sheet structure has an inner surface intended to be directed towards the bone and an outer surface intended to be directed away from the bone. The geometrical features of the cavity formed between the inner surface of the device and the initial bone surface when the device is installed at the intended location is further used to improve and plan the treatment. The device is customized by means of digital planning based on the initial and the optimal bone volume for the intended treatment. Modifications of the device can be introduced to facilitate a combined installation of dental implants with the device.

The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.

The present invention provides a method for producing neural crest cells from pluripotent stem cells, the method comprising: a step (1) of subjecting pluripotent stem cells to suspension culture in a culture medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) performing suspension culture in a culture medium containing an ALK inhibitor and a GSK-3beta inhibitor.

The present invention relates to a bone graft composition in which a lappaconitine derivative is surface-adsorbed on a scaffold comprising tricalcium phosphate (TCP) and hydroxyapatite (HA). In the composition of the present invention, the osteogenesis-promoting properties of the lappaconitine derivative are combined with the osteoconductivity of the TCP / HA scaffold, thereby improving problems such as high-concentration adverse effects, unstable adsorption patterns, and localized excessive formation, which occur in existing protein-based osteogenic factors.

This invention relates to the field of sand core forming, and more particularly to a method for manufacturing an ultrathin annular air duct core. Addressing the problems of poor core bone positioning accuracy in existing technologies, which easily leads to core bone leakage during sand filling and thus scrapping of handmade cores, this invention provides a method for manufacturing an ultrathin annular air duct core. This method is simple to operate, facilitates core bone forming, and achieves relatively accurate dimensions, making it suitable for forming small-sized handmade cores with small sand volumes. The mesh-like core bone dimensions provide sufficient support strength for thin-surface sand cores; the core bone positioning is accurate, preventing core bone misalignment; the core bone is welded using a 3D-printed sand mold, resulting in precise core bone dimensions, suitable for handmade core production with very small sand volumes and where core bone drawings are inconvenient to annotate.

The present application belongs to the field of medicine, and particularly relates to a new target point NCSTN for regulating bone metabolism and application of an agonist of the target point in preparation of a medicine for preventing or treating osteoporosis. One object of the present application is to provide a new target point NCSTN for regulating bone metabolism and application of the target point in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. The present application first discovers a mechanism of treating osteoporosis by using an agonist of NCSTN, and has the effect of inhibiting mature differentiation of osteoclasts and promoting bone formation function of osteoblasts. This is very different from the previously reported mechanism of single inhibition of bone resorption or single promotion of bone formation, and the treatment of osteoporosis by simultaneously acting on bone resorption and bone formation can greatly reduce adverse reactions of the body to the medicine.

This invention discloses a method for preparing a strontium titanate modified layer on the surface of zirconia based on an impregnation-heat treatment method, comprising: (1) mixing titanium sulfate, urea and water to obtain a precursor liquid A, placing zirconia ceramic in the precursor liquid A, heating to boiling and maintaining for a period of time, then removing the zirconia ceramic, and after heat treatment A, preparing a titanium dioxide film on the surface of zirconia; (2) mixing H2O2 aqueous solution, ammonia and deionized water, adding metatitanic acid and stirring to dissolve, obtaining a precursor liquid B, placing the zirconia with the titanium dioxide film in the precursor liquid B, and allowing it to stand and react for a period of time at room temperature, depositing zirconia modified with a titanium dioxide precursor layer; (3) dissolving strontium acetate, or a mixed salt composed of calcium acetate and / or magnesium acetate and strontium acetate in deionized water to obtain an impregnation treatment solution, placing the zirconia modified with the titanium dioxide precursor layer in the impregnation treatment solution, allowing it to stand and react for a period of time, and then removing it, and after heat treatment B, preparing a strontium titanate modified layer on the surface of zirconia. The strontium titanate layer prepared on the surface of zirconia ceramic in this invention is tightly attached to the zirconia substrate and has high hydrophilicity, which is conducive to the adhesion of proteins and cells in the human body. At the same time, it can release active factors such as strontium ions for a long time to promote bone formation and bone regeneration at the implantation site, ultimately enhancing the osseointegration capacity of the zirconia implant.

The application relates to the technical field of orthopedic repair material preparation, and discloses a sterile preparation and injection device for autologous red blood cell drug-loaded blood gel, which comprises a cross bolt mixer, a multimodal injector combined with a composite syringe and a mixing flow channel, the cross bolt is internally integrated with a microfluidic mixing channel, a vertical shaft direction and a coronal shaft direction are respectively connected with a main injector and a drug-loaded injector, when the red blood cell-rich plasma enters the bolt, longitudinal shear force is generated through a spiral flow channel, so that bone morphogenetic protein suspension is vertically injected into a main flow channel through a one-way valve structure, equal ratio mixing of 4:1 is realized in the spiral channel, and the whole mixing process is completed in a closed system. The device has the advantages of realizing accurate and uniform mixing of the red blood cell-rich plasma and the drug in a sterile environment, reducing the risk of bacterial contamination, being capable of directly injecting and filling bone defects for the prepared blood gel, being excellent in biological safety and compatibility, and being low in preparation cost and simple in process.

This application applies to the fields of computer-aided medical technology and surgical robot technology, and provides a knee-preserving surgical robot and its control method. The knee-preserving surgical robot includes: a preoperative planning unit, used to determine the osteotomy plane based on the surgical key points on the patient's three-dimensional bone model, and plan the correction angle after establishing the target force line; an intraoperative execution unit, used to perform osteotomy operation according to the osteotomy plane with the assistance of a navigation system, so that the angle after the osteotomy site is stretched meets the requirements of the correction angle; and a postoperative evaluation unit, used to simulate postoperative bone images, calculate the force line angle based on the simulated postoperative bone images, and adjust the correction angle formed by the actual osteotomy according to the force line angle; tracers are respectively installed on the proximal and distal ends of the patient's bone and the corresponding surgical tools, and the navigation system provides position data for the operations performed by the intraoperative execution unit and the postoperative evaluation unit by tracking the position changes of the tracers.

The invention discloses application of Crlf2 in preparation of a medicine for preventing, relieving and / or treating osteoporosis, and relates to the technical field of new application of medicines. According to the application of the Crlf2 in preparation of the medicine for preventing, relieving and / or treating the osteoporosis, the key regulation and control function of the Crlf2 in differentiation of bone tissue related cells and osteoporosis diseases is disclosed for the first time, and a new theoretical perspective is provided for pathogenesis of the osteoporosis; it is found that the Crlf 2 inhibitor (such as a specific antibody or a small molecule inhibitor) can be directly used for preparing the efficient and high-targeting anti-osteoporosis medicine, the limitation of existing treatment means (such as bisphosphonate medicine inhibiting bone resorption but not promoting bone formation) is broken through, and accurate intervention aiming at a specific signal channel is achieved.

The invention discloses a construction method and application of an adriamycin-induced zebrafish osteoporosis-like model, and the construction method comprises the following steps: by utilizing the characteristics of transparency and rapid bone development of zebrafish embryos and juvenile fishes, selecting the zebrafish embryos of 2dpf, and culturing the zebrafish embryos to 6dpf in an adriamycin aqueous solution of 20 mu m, so as to obtain the adriamycin-induced zebrafish osteoporosis-like model. Therefore, the visual zebrafish osteoporosis-like model is efficiently constructed, juvenile fish bodies are transparent, imaging is visual, bone development changes can be observed in vivo in real time, and visual evaluation of bone development injuries is achieved. The built zebrafish osteoporosis-like model clearly shows the systematic inhibition effect of chemotherapy drugs on bone formation and mineralization, has the advantages of being short in building period, easy and convenient to operate, high in repeatability and sensitive to drug reaction, can be used for rapid dose screening and intervention experiments, and has good application prospects. The method has great application potential in research of pathogenesis of CIOP, screening of anti-osteoporosis drugs and evaluation of curative effect of the anti-osteoporosis drugs.

The invention discloses application of black bean source oligopeptide in preparation of a product for preventing / treating osteoporosis, and belongs to the technical field of bioactive peptides. According to the black bean source oligopeptide helpful for improving osteoporosis, the black bean source oligopeptide comprises oligopeptide KGVG and / or oligopeptide KIGT; wherein the amino acid sequence of the oligopeptide KGVG is Lys-Gly-Val-Gly, and the amino acid sequence of the oligopeptide KIGT is Lys-Ile-Gly-Thr; the black bean source oligopeptide can directly up-regulate osteoblast activity, enhance expression of BMP-2 and Runx2, improve the level of bone formation marker osteocalcin, remarkably improve the bone density and bone microstructure of ovariectomized mice and enhance bone mechanical strength, is non-toxic to other tissues, can be used as an effective nutrition strategy for treating and relieving osteoporosis, and has broad application prospects. A scientific basis is provided for efficient utilization of the black bean source bioactive peptide.

This application provides a composition containing PENK protein and its application in promoting osteoblast osteogenic differentiation. Compared with the prior art, this application has the following advantages: The pro-PENK recombinant protein and the PENK-containing composition provided in this application, after being applied to cells with osteogenic potential, enhance osteogenic performance through interaction with CBFB protein, and can significantly promote osteogenic differentiation. Compared with the existing bone morphogenetic protein 2 (BMP recombinant protein), the osteogenic effect is superior. Furthermore, experiments have verified that the osteogenic differentiation effect of pro-PENK recombinant protein on osteoblasts is dose-dependent. This application further verifies that the combined use of low doses of PENK recombinant protein and BMP recombinant protein has a more significant cellular osteogenic effect than the use of either at high doses alone.

A polypeptide or a modifier thereof having an effect of promoting bone formation; can be used for preventing and / or treating bone diseases.

The invention provides application of xylotetraose or a composition of xylotetraose and nystose in preparation of an anti-osteoporosis product. The invention discloses the synergistic effect of the xylotetraose and the nystose in the aspect of osteoporosis resistance for the first time. When the zebrafish bone mineral composition and the zebrafish bone mineral composition are combined for use, the bone mineralization degree of zebrafish can be remarkably enhanced, the mineralization rate is increased, osteoblast activity is improved, bone metabolic disorder is effectively reversed, and the synergistic anti-osteoporosis potential of the zebrafish bone mineral composition is fully proved. Meanwhile, the invention also discloses the anti-osteoporosis effect of the xylotetraose for the first time, and the xylotetraose can promote bone mineralization, promote bone formation, inhibit bone resorption and regulate bone metabolism balance to a certain extent.

The invention relates to application of a TRMT10C agonist TM3 in preparation of a medicine for treating senile osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the TRMT10C agonist TM3 is used for treating senile osteoporosis for the first time. A mouse experiment verifies that the TRMT10C agonist TM3 can inhibit bone loss of a mouse with osteoporosis, increase the bone density, the number of bone trabecula and the volume fraction of the bone trabecula, reduce the separation degree of the bone trabecula and promote bone formation. It is fully proved that the TRMT10C agonist TM3 can be used for treating the senile osteoporosis caused by the fact that the osteogenesis rate is remarkably reduced due to age increase, and therefore the TRMT10C agonist TM3 can be used for preparing the medicine for treating the senile osteoporosis and has important significance in clinical treatment of the senile osteoporosis in the future.

The application provides a composition for promoting bone health and bone formation, and application and products thereof, and belongs to the field of food. The composition of the application is composed of 2'-fucosyllactose, osteopontin and a calcium source, wherein the osteopontin is 1-5 parts, the 2'-fucosyllactose is 1-50 parts and the calcium source is 0.05-50 parts by weight. The composition of the application shows a good synergistic effect in promoting calcium absorption, and can be used for increasing bone density, preventing and treating osteoporosis and the like.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) and application thereof. According to the invention, by analyzing and comparing the expression conditions of the long-chain non-coding RNA in a wild type mouse and an ER beta gene knockout mouse, the long-chain non-coding RNA participating in the regulation and control of the osteogenic differentiation of the bone marrow mesenchymal stem cells, namely the long-chain non-coding RNA MSTRG.47495.1 (lncRNA MSTRG.47495.1), is found. Overexpression of the long-chain non-coding RNA in the bone marrow mesenchymal stem cells can effectively promote osteogenic differentiation of the bone marrow mesenchymal stem cells, enhance bone regeneration and promote bone defect repair of rats with skull injury. On the basis, the long-chain non-coding RNA can promote osteogenic differentiation of bone marrow mesenchymal stem cells and enhance bone regeneration, and is used for preparing medicines for treating bone metabolic diseases and bone formation disorder related diseases. In addition, the long-chain non-coding RNA can also be used for construction of bone organs.

Disclosed are a method and an apparatus for examining bone formation of alveolar bone using an oral scanner having a tomographic function. The bone formation inspection method for alveolar bone comprises: a step of filling a bone graft material into an alveolar bone to be subjected to bone graft, suturing gingiva, and then acquiring a surface shape image of a portion where the alveolar bone is formed by using a surface shape acquisition optical system; a step for acquiring an internal cross-sectional image showing the state of the alveolar bone and the bone graft by means of an internal cross-sectional acquisition optical system at a predetermined position in the acquired surface shape image; a step of moving the oral scanner to acquire a gingival surface shape after a predetermined period of time has elapsed, and when the gingival surface shape at a position at which the internal cross-sectional image was previously acquired is detected, acquiring an internal cross-sectional image showing the state of the alveolar bone and the bone graft at the position using an internal cross-sectional acquisition optical system of the oral scanner; and a step for comparing the internal cross-sectional images acquired at predetermined intervals.